ENTRY       D11771                      Drug
NAME        Tezepelumab (USAN/INN);
            Tezepelumab (genetical recombination) (JAN);
            Tezepelumab-ekko;
            Tezspire (TN)
PRODUCT     TEZSPIRE (Amgen)
FORMULA     C6400H9844N1732O1992S52
EXACT_MASS  144498.7714
MOL_WEIGHT  144588.4306
SEQUENCE    (Heavy chain)
            QMQLVESGGG VVQPGRSLRL SCAASGFTFR TYGMHWVRQA PGKGLEWVAV IWYDGSNKHY
            ADSVKGRFTI TRDNSKNTLN LQMNSLRAED TAVYYCARAP QWELVHEAFD IWGQGTMVTV
            SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
            SSGLYSLSSV VTVPSSNFGT QTYTCNVDHK PSNTKVDKTV ERKCCVECPP CPAPPVAGPS
            VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVQFNWYV DGVEVHNAKT KPREEQFNST
            FRVVSVLTVV HQDWLNGKEY KCKVSNKGLP APIEKTISKT KGQPREPQVY TLPPSREEMT
            KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPMLD SDGSFFLYSK LTVDKSRWQQ
            GNVFSCSVMH EALHNHYTQK SLSLSPGK
            (Light chain)
            SYVLTQPPSV SVAPGQTARI TCGGNNLGSK SVHWYQQKPG QAPVLVVYDD SDRPSWIPER
            FSGSNSGNTA TLTISRGEAG DEADYYCQVW DSSSDHVVFG GGTKLTVLGQ PKAAPSVTLF
            PPSSEELQAN KATLVCLISD FYPGAVTVAW KADSSPVKAG VETTTPSKQS NNKYAASSYL
            SLTPEQWKSH RSYSCQVTHE GSTVEKTVAP TECS
            (Disulfide bridge: H22-H96, H136-L213, H149-H205, H224-H'224, H225-H'225, H228-H'228, H231-H'231, H262-H322, H368-H426, H'22-H'96, H'136-L'213, H'149-H'205, H'262-H'322, H'368-H'426, L22-L87, L136-L195, L'22-L'87, L'136-L'195)
  TYPE      Peptide
REMARK      Therapeutic category: 2290
            ATC code: R03DX11
            Product: D11771<JP/US>
EFFICACY    Anti-inflammatory, Anti thymic stromal lymphopoietin antibody
  DISEASE   Asthma [DS:H00079]
  TYPE      Monoclonal antibody
COMMENT     Treatment of asthma and atopic dermatitis
TARGET      TSLP [HSA:85480] [KO:K05436]
  PATHWAY   hsa04060(85480)  Cytokine-cytokine receptor interaction
            hsa04630(85480)  JAK-STAT signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             R RESPIRATORY SYSTEM
              R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
               R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
                R03DX Other systemic drugs for obstructive airway diseases
                 R03DX11 Tezepelumab
                  D11771  Tezepelumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Respiratory Tract/Pulmonary Agents
              Respiratory Tract Agents, Other
               Immunomodulators
                Tezepelumab
                 D11771  Tezepelumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              22  Respiratory organ agents
               229  Miscellaneous
                2290  Miscellaneous
                 D11771  Tezepelumab (USAN/INN); Tezepelumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               CSF and other factors
                TSLP
                 D11771  Tezepelumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11771
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11771
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11771
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11771
DBLINKS     CAS: 1572943-04-4
            PubChem: 405226637
///
